Dysosmobacter welbionis as Next Generation Probiotics
Background D. welbionis and Diseases Services Products Brochures FAQs Resources
Therapeutic candidates such as Akkermansia, Lactobacillus, Bifidobacterium, and Dysosmobacter welbionis (D. welbionis) have D. welbionis. Creative Biolabs offers well-established and innovative One-Stop-Shop live biotherapeutic products (LBP) solutions. We are flexible to meet the unique needs of LBP client projects about D. welbionis.
Introduction of D. welbionis
Fig.1 Scanning electron micrographs of cells of strain J115T in late exponential phase.1
D. welbionis is a novel species of Ruminococcaceae. The cells are obligatory anaerobic, non-pigmented, non-spore forming, non-motile, and Gram-stain-negative. Cells form straight rods mainly 1.8-3.0μm but often form elongated rods whatever the growing phase. Colonies on solid modified YCFA after 72h of incubation at 37℃ under anaerobic conditions are punctiform, cream, translucent, circular, entire, slightly convex, and smooth. The type strain, J115T (=DSM 106889T=LMG 30601T) was isolated from a faecal sample from a healthy 25-year-old female in July 2017. It presents in 70% of the general population at a relatively high abundance (0-9%). Strain J115T produced acid from myo-inositol but not from Dglucose, D-ribose or D-xylose. Butyric acid was the major end-product of myo-inositol. The genomic DNA G+C content was 58.92 mol%. Strain J115T was also related to the not-yet-cultured bacterium Oscillospira guilliermondii (92-93%similarity). It is important to note that this bacterium has been grown in a well-defined medium suitable for use of the bacterium in humans. This makes it possible to bypass the difficulties previously faced in investigating A. muciniphila.
Recently, D. welbionis was also thought to have beneficial effects similar to those of A. muciniphila. Supplementation with live D. welbionis J115T (1.0×109 CFU daily) in mice, but not with the same pasteurized strain, induced a decrease in fat mass gain, insulin resistance, and white adipose tissue hypertrophy and inflammation. These results suggest that D. welbionis J115T directly and beneficially influences host metabolism and is a strong candidate for the development of next-generation beneficial bacteria targeting obesity and associated metabolic diseases.
Fig.2 Live D. welbionis J115T prevents diet-induced obesity in mice. 2
What Services Can We Provide for D. welbionis at Creative Biolabs?
D. welbionis Related Products at Creative Biolabs
We supply a variety of D. welbionis strains of different preservation numbers as below. If you need other strains, please contact us.
-
Customized strain culture supernatant. (e.g.: for animal research)
-
Customized strain lyophilized powder containing certain CFU. (e.g.: for animal research)
Creative Biolabs will work with you as part of your team to not only provide comprehensive quality data but also timely and effective solutions to any challenges that you face in the development of D. welbionis. Please feel free to contact us. We are happy to discuss more details about D. welbionis with you.
Brochures
FAQs
What is D. welbionis and why is it considered a promising probiotic?
D. welbionis is a Gram-negative bacterium found in the human gut microbiome. It has been identified as a next-generation probiotic due to its unique metabolic capabilities and potential to modulate gut health and immune responses. Research indicates that it can contribute to gut microbiome stability and offer benefits such as enhanced digestion and immunity.
How can D. welbionis be utilized in preclinical research?
D. welbionis can be used in preclinical research to evaluate its effects on gut microbiota composition, immune responses, and overall health. Researchers can assess its potential in preventing or treating gastrointestinal disorders and other related conditions. Its use in animal models can provide valuable data before progressing to clinical trials.
What specific services do you offer for studying D. welbionis?
We offer comprehensive services for studying D. welbionis, including strain characterization, metabolic profiling, and in vitro assays to evaluate its probiotic potential. Our services also include gut microbiome analysis and immune response studies to provide a thorough understanding of its effects and mechanisms.
Are there any safety concerns associated with using D. welbionis in research?
Currently, D. welbionis has demonstrated a favorable safety profile in preliminary studies. However, as with any new probiotic strain, thorough safety assessments are recommended in preclinical research settings to ensure it does not produce adverse effects. Our services include detailed safety evaluations as part of the research process.
Can D. welbionis be customized for specific research needs?
Yes, D. welbionis can be customized for specific research applications. We offer tailored solutions including strain modification, specific metabolic profiling, and customized assay development to meet the unique requirements of your research projects. This flexibility enhances the relevance and impact of your studies.
Resources
References
-
Le, R.T.; et al. Dysosmobacter welbionis gen. nov., sp. nov., isolated from human faeces and emended description of the genus Oscillibacter. International journal of systematic and evolutionary microbiology. 2020, 70(9): 4851-4858.
-
Le, R.T et al. Dysosmobacter welbionis is a newly isolated human commensal bacterium preventing diet-induced obesity and metabolic disorders in mice. Gut. 2022, 71(3): 534-543.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
